Pharmaceuticals Policy and Law - Volume 12, issue 3-4 - Journals

Pharmaceuticals Policy and Law - Volume 12, issue 3-4

The new international review, Pharmaceuticals Policy and Law, appears with the aim of studying and evaluating the legal status of medicinal products in the European Union, and its implications in other markets such as the USA and Japan, without neglecting the specific problems of developing countries.

Pharmaceuticals Policy and Law intends to participate in the process of world convergence of pharmaceutical legislation helped by a network of academic centers specializing in pharmaceutical law, without omitting a scientific, economic and social approach to medicinal products.

The specificity of medicinal products conditions their legal status. Legislation regulating other goods cannot be applied to them. To begin with, they are the result of scientific and technical innovation. Research policies determine their progress. The pharmaceutical industry is, by nature, multinational. But, next to these global trends, different traditions still remain at a national level. Within the EU, barriers to free trade in medicinal products still remain despite more than thirty years of harmonisation. The social dimension of medicinal products is complex and very significant in the preoccupations of our societies. Patenting is essential but not sufficient. The life-cycle of medicinal products is protected by professional responsibility, required in the general concept of health safety. It is important to remember their ethical dimension, including research and innovation in new fields such as genetic manipulation and biotechnology, which requires social consent to preserve human dignity and fundamental rights.

Show:

results per page

How is Italian pharmacy changing and what is the new direction: A modern health post or a drug-store?

Authors: Cicconetti, Pierandrea

Article Type: Research Article

Abstract: List of the new health (professional) and social (administrative) services provided by pharmacy according to new Italian law and National Health Service Authority; weak and strength points, examination of all the aspects. New health services are important to give effort to the pharmacist role, on the other hand the social ones need time and human resources to run. Some pharmacy provides a wide range of services for free already and small pharmacies cannot compete …due to problems dealing with the surface of the shop or with the number of employees. New strategies oriented to help and protect small pharmacies are vital, but the most important thing is to create a network of pharmacies that will offer new services; everyone must join it, we do not want pharmacies lack in knowledge in the future and not professional. Show more

Keywords: National health service, region, pharmacy, health (professional) service and social (administrative) service

DOI: 10.3233/PPL-2010-0306

Citation: Pharmaceuticals, Policy and Law, vol. 12, no. 3-4, pp. 303-306, 2010

Price: EUR 27.50

The new Spanish regulation of the medicinal industry

Authors: Gillard, Juan | Escudero, Concepción

Article Type: Research Article

DOI: 10.3233/PPL-2010-0302

Citation: Pharmaceuticals, Policy and Law, vol. 12, no. 3-4, pp. 307-311, 2010

Price: EUR 27.50

The role of the pharmacist in the determination of pharmacotheraphy costs: Ischemic cardiopathy patients with smoking habits

Article Type: Research Article

Abstract: In the last decades the pharmacist has played a main role in the policies of costs containment in the health sector. The present study has been designed to assess this role in the costs containment of the pharmacological treatments of patients at a Coronary Care Unit (CCU) of a public hospital in Argentina, through an analitic and retrospective study. It has been observed that the pharmacist could determine in all the service a saving of $ 3,393.03 buying …the prescriptive drugs at minimum prices during the analized period. However, it has been proved that there are costs which the pharmacist cannot modify, as in the case of certain risk factors that may increase the pharmacological costs in the treatment of a pathology. This cost variation has been proved in ischemic cardiopathy patients with smoking habits. Show more

Keywords: Role of the pharmacist, costs containment, ischemic cardiopathy, smoking habits

DOI: 10.3233/PPL-2010-0305

Citation: Pharmaceuticals, Policy and Law, vol. 12, no. 3-4, pp. 313-319, 2010

Price: EUR 27.50

Display: 10 | 50 | 100 items per page

Terms & conditions
Privacy policy
Copyright ©2024 IOS Press All rights reserved.

North America

IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA

Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]

For editorial issues, like the status of your submitted paper or proposals, write to [email protected]

Europe

IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands

Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]

For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]

Asia

Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China

Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]

For editorial issues, like the status of your submitted paper or proposals, write to [email protected]

如果您在出版方面需要帮助或有任何建, 件至: [email protected]

Built on the Scolaris platform by: